Siemens Healthineers' Boss Bets on Bedside Value Over AI Buzzwords
Published on 08/24/2026 at 18:05 | Redaktion boerse-global.de
When Bernd Montag talks about artificial intelligence, he sounds less like a tech evangelist and more like a clinician who has seen too many promising tools fail to change patient outcomes. The chief executive of Siemens Healthineers has explicitly ruled out a standalone AI strategy, arguing that the technology is a means to an end rather than a destination in itself. "We don't need an AI strategy," he said in an interview published over the weekend, according to dpa.
The logic is straightforward: AI should serve medicine, not the other way around. Montag is steering the medical technology group toward three specific disease areas — oncology, cardiovascular conditions and stroke care — where targeted applications can deliver measurable improvements. The emphasis, he insists, is on data quality rather than data volume, and on keeping physicians firmly in the decision-making loop.
Early pilot work appears to support the approach. In radiology trials, the interpretation of chest CT scans was accelerated by up to 25 percent, while the cognitive load on doctors dropped by 16 percent. Those figures, Montag suggests, are what matter — not grand pronouncements about technological superiority.
The timing of the comments is notable. The EU's AI Act classifies medical AI applications as high-risk, with compliance obligations kicking in by 2027. Companies that have already focused on narrow, well-documented use cases rather than sprawling AI programs may find themselves in a stronger regulatory position when those rules take effect.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
There is also a broader industry context. Capital expenditure on AI infrastructure is escalating across sectors, with Nvidia having announced price increases for its server chips from 2027. Montag's pragmatic counter-play — letting technology follow clinical need rather than the reverse — stands in deliberate contrast to that arms race mentality.
The company's scale affords him that luxury. Siemens Healthineers, a DAX constituent since 2021, employs roughly 75,000 people and generated revenue of more than €23 billion in the last fiscal year. In the third quarter of 2026, sales grew 2.8 percent year-on-year, with an EBIT margin of 19.1 percent. Those fundamentals give management room to be selective about where and how AI gets deployed.
Investors have taken a measured view of Montag's messaging. The stock edged up 0.9 percent at one point in XETRA trading on Monday, reaching €40.56, before settling at €40.42 — a gain of 1.1 percent on the day. That follows Friday's close of €39.97, which itself represented a 0.4 percent advance. Over the past 30 days, the shares have climbed roughly 15 percent, a rally that suggests the market had already begun to reward the company's strategic direction before the CEO's latest remarks.
Still, the recovery has ground to cover. The shares sit well above their 52-week low of €32.84 but remain roughly 20 percent below the October high of €49.78. The gap between the current price and that peak underscores how far sentiment has swung over the past year — from the spring trough to the recent improvement in analyst assessments.
For shareholders, Montag's stance is a signal of continuity rather than transformation. Siemens Healthineers is choosing to embed AI into existing workflows and proven diagnostic strengths instead of marketing it as a standalone growth engine. Whether that disciplined approach pays off while competitors pour billions into broader AI capabilities is a question that will likely take several fiscal years to answer. The real test, as ever, will be whether the strategy shows up in the growth numbers — not in the rhetoric.
Ad
Siemens Healthineers Stock: New Analysis - 24 August
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
